本文關(guān)鍵詞： 綜述 心房顫動(dòng) 腎疾病 血栓形成 出血　出處：《中國循環(huán)雜志》2016年02期 　論文類型：期刊論文

【摘要】：非瓣膜性心房顫動(dòng)(房顫)是最常見的心律失常,卒中是房顫嚴(yán)重并發(fā)癥之一。終末期腎臟病(ESRD)與房顫有共同的危險(xiǎn)因素。有研究報(bào)道,ESRD可通過改變多種生理機(jī)制增加房顫患者的卒中及出血風(fēng)險(xiǎn),并與遠(yuǎn)期預(yù)后相關(guān)�？鼓委熥鳛榉款澔颊咦渲械囊患�(jí)及二級(jí)預(yù)防可使患者獲益,但如何準(zhǔn)確細(xì)致地評(píng)估房顫伴ESRD患者抗凝治療的獲益和風(fēng)險(xiǎn)仍不明確,多項(xiàng)評(píng)價(jià)房顫伴ESRD患者抗凝治療的臨床實(shí)驗(yàn)結(jié)果不盡相同。本文就ESRD對(duì)非瓣膜性房顫患者發(fā)生卒中與出血事件的影響進(jìn)行綜述。
[Abstract]:Non-valvular atrial fibrillation (AF) is the most common arrhythmia, stroke is one of the serious complications of AF. ESRD has a common risk factor with AF. ESRD can increase the risk of stroke and hemorrhage in patients with atrial fibrillation by changing many physiological mechanisms and is related to long-term prognosis. Anticoagulant therapy can benefit patients as the primary and secondary prevention of stroke in patients with atrial fibrillation. However, how to accurately and meticulously assess the benefits and risks of anticoagulant therapy in patients with atrial fibrillation with ESRD remains unclear. The clinical trial results of anticoagulant therapy in patients with atrial fibrillation associated with ESRD are different. This article reviews the effects of ESRD on stroke and bleeding events in patients with non-valvular atrial fibrillation.
【作者單位】： 南昌大學(xué)第二附屬醫(yī)院心內(nèi)科;
【分類號(hào)】：R541.75;R692.5
【正文快照】： 心房顫動(dòng)(房顫)是臨床上常見的心律失常,可顯著增臨床研究發(fā)現(xiàn),房顫伴ESRD患者卒中/全身血栓事加患者的卒中風(fēng)險(xiǎn)。有報(bào)道稱,20%的卒中與房顫患者左心件發(fā)生率高于腎功能正常的房顫患者[風(fēng)險(xiǎn)比(HR):1.83,房血栓形成有關(guān)[1]。近年來,終末期腎臟病(ESRD)對(duì)房顫95%可信區(qū)間(CI):1.，

本文編號(hào)：1445854